Please login to the form below

Not currently logged in
Email:
Password:

S-A to cut US pharma workforce

Sanofi-aventis has announced plans to cut about 25 per cent of its US Pharmaceutical Operations workforce, laying off about 1,700 workers

Sanofi-aventis (S-A) has announced plans to cut about 25 per cent of its US Pharmaceutical Operations workforce, laying off about 1,700 workers.

In addition, the company said its US Pharmaceuticals business will narrow its focus to diabetes, atrial fibrillation and oncology.

"This restructuring will allow the company to focus resources and people on these key areas," the company said. "It will also position the company for growth following the impact of patent expiries, increase business development and other innovative partnerships, and ensure appropriate investment in late-life cycle products."

The US patent on S-A's cancer drug Taxotere (docetaxel) expires next month, and the patent on the blood-thinner Plavix (clopidogrel), the company's top-selling drug, is due to expire in 2011.

S-A currently employs 6,900 people in its US Pharmaceutical Operations division and 13,000 in the US in total.

Separately, the board of the US biotech company Genzyme announced that it has again rejected a takeover bid from Paris-based S-A, reiterating that it believes that the offer of $69 per share fails to appropriately recognise the value of the company. S-A last week initiated a hostile takeover attempt and set December 10 as the deadline for Genzyme stockholders to tender their shares.

11th October 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hayward Medical Communications

Hayward Medical Communications has been supporting partners in every sector of the healthcare industry to deliver evidence-based, clinically relevant and...

Latest intelligence

Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...
The Future of Pharma sales: fast forward to 2029
Change is inevitable, and necessary, for growth in business....

Infographics